Eli Lilly (LLY.N) announced a $1.2 billion investment to expand its manufacturing site in Carolina, Puerto Rico, as part of a broader $50 billion U.S. manufacturing initiative aimed at boosting domestic production capacity and mitigating potential tariff risks.
The upgraded facility will produce Orforglipron, Lilly’s upcoming oral weight-loss treatment expected to be submitted for global regulatory approval by the end of 2025. It will also support the company’s growing portfolio in cardiovascular, diabetes, oncology, and immunology therapies.
The expansion will create 100 skilled positions in advanced manufacturing and up to 1,000 construction jobs. Construction begins in 2026, with oral drug production slated for late 2028.
This move follows Lilly’s announcement earlier this year to invest $27 billion in four new U.S. manufacturing sites, including facilities in Texas and Virginia, as the company reinforces its U.S. supply chain amid evolving trade policies.